Anixa Biosciences, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended April 30, 2022. Financial statement amounts are in thousands of dollars except per-share data and share counts.
Business context
Anixa is a development-stage biotechnology company focused on cancer therapeutics and vaccines, plus COVID-19 antiviral drug discovery. Its programs include CAR-T therapy for ovarian cancer, breast and ovarian cancer vaccines, and antiviral candidates. It reported no revenue for the quarter or six-month period from its current programs.
Financial performance and liquidity
| Metric | Three months ended April 30, 2022 | Six months ended April 30, 2022 | Prior comparable period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 and $513, respectively |
| Research and development | $1,735 | $3,573 | $1,022 and $1,850 |
| General and administrative | $1,854 | $3,896 | $1,415 and $2,948 |
| Net loss | $(3,588) | $(7,467) | $(2,437) and $(4,669) |
| Net loss per common share | $(0.12) | $(0.24) | $(0.08) and $(0.17) |
Gross and operating margins are not meaningful because the company had no current-period revenue. Operating costs were $3.589 million for the quarter and $7.469 million for six months. Non-cash share-based compensation was $1.681 million and $4.036 million, respectively.
At April 30, 2022, cash and cash equivalents were $27.732 million and short-term investments were $4.499 million, totaling $32.231 million, compared with $35.727 million at October 31, 2021. Six-month operating cash use was $3.503 million; investing activities provided $2.100 million, mainly from net maturities of investments; financing activities provided $7,000. Total liabilities were $1.391 million, primarily lease obligations and accrued expenses; the filing reports no borrowings.
Changes versus prior period
- Quarterly net loss increased to $3.588 million from $2.437 million; six-month net loss increased to $7.467 million from $4.669 million.
- R&D and G&A expenses increased in both comparison periods. Management attributed much of the increase to employee and consultant share-based compensation, compensation costs, and investor/public relations spending.
- Six-month revenue declined from $513,000 in 2021, which came from a one-time legacy technology license; there was no revenue in 2022. Associated royalties and legal/licensing expenses also fell from $385,000 to zero.
Outlook, risks and notable items
- Management said available cash, cash equivalents, short-term investments and expected cash flows should fund activities for at least the next 12 months, based on information available June 10, 2022. It cautioned that projections may differ and future equity or debt financing may be needed, potentially diluting shareholders.
- The ovarian cancer CAR-T Phase 1 trial began patient recruitment in March 2022; the planned study includes 24–48 patients and is estimated to take two to four years. The breast cancer vaccine Phase 1 trial began dosing in October 2021; management reported initial indications of an immune response and estimated completion by year-end 2022.
- The ovarian cancer vaccine’s preclinical work is supported by the NCI PREVENT program, which management said should require no material company expenditure. The antiviral program remains in discovery and optimization; company-reported laboratory results suggesting greater inhibition of a viral enzyme than nirmatrelvir are not clinical efficacy evidence.
- The company does not expect near-term revenue from its therapeutic or vaccine programs; eventual licensing may take years, may depend on positive clinical results, and may not occur.
- Risks include clinical and regulatory uncertainty, recruitment and development timelines, collaboration-partner disruptions and COVID-19 developments, and potential need for additional capital. The filing reported no material changes to previously disclosed risk factors and no material pending legal proceedings apart from patent-rights enforcement matters.
Investor verification priorities
- Track quarterly cash burn, investment balances and whether management’s stated 12-month funding expectation remains supported.
- Verify trial enrollment, safety, immune-response and other clinical updates, and compare progress with disclosed timelines.
- Assess expense growth excluding substantial non-cash compensation and monitor the impact of stock-option awards and potential dilution.
- Confirm whether any licensing revenue, external funding, or material changes in collaboration and program plans emerge in subsequent filings.